SINGULAIR 4MG GRANULES 28''S **

A valid prescription needed upon order collection
Singulair-Paediatric 4 mg Sachet 28P
Singulair
Singulair-Paediatric 4 mg Sachet 28pcs
 
SINGULAIR 4 MG (PAED.) 14 SACHETS Details
The best price of SINGULAIR 4 MG (PAED.) 14 SACHETS by Seif in Egypt is 70 EG
Similar products to SINGULAIR 4 MG (PAED.) 14 SACHETS are sold at Fouda, vitameno with prices starting at 60 EGP
The first appearance of this product was on Aug 21, 2014
Amongst similar products of SINGULAIR 4 MG (PAED.) 14 SACHETS the cheapest 
* SINGULAIR (Montelukast, MSD) 4 mg Paediatric Oral Granules. 14 Sachets. Net Weight 500mg/sachet. * Composition: Each sachet contains: montelukast sodium equivalent to 4 mg m
SINGULAIR 4 MG (PAED.) 14 SACHETS
SINGULAIR (montelukas, sodium) is a selective and orally active leukotriene receptor antagonist that specifically inhibits the cysteinyl leukotriene Cysl T1 receptor.
 INDICATIONS :
SINGULAIR is indicated in adult and pediatric patients 6 months of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction.
SINGULAIR is indicated for the relief of daytime and nighttime symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and order
DOSAGE AND ADMINISTRATION :
SINGULAIR should be taken once daily. For asthma, the dose should be taken in the evening. For allergic rhinitis, the time of administration may be individualized to suit patient needs.
Patients with both asthma and allergic rhinitis should take only one tablet daily in the evening.
Adults 15 Years of Age and Older with Asthma and/or Allergic Rhinitis The dosage for adults 15 years of age and older is one 10-
mg tablet daily. Pediatric Patients 6 to 14 Years of Age with Asthma and/or Allergic Rhinitis
The dosage for pediatric patients 6 to 14 years of age is one 5-mg chewable tablet daily. Pediatric Patients 2 to 5 Years of Age with Asthma andlor Allergic Rhinitis The dosage for pediatric patients 2 to 5 years of age is one 4-mg chewable tablet daily or one packet of 4-mg oral granules daily.
Pediatric Patients 6 Months to 2 Years of Age with Asthma or Perennial Allergic Rhinitis The dosage for pediatric patients 6 months to 2 years of age is one packet of 4-mg oral granules daily.
Administration of oret granules:
SINGULAIR oral granules can be administered either directly in the mouth, mixed with a spoonful of cold or room temperature soft food (e.g., applesauce), or dissolved in 1 teaspoonful (5 ml) of cold or room temperature baby formula or breast milk. The packet should not be opened
until ready to use after opening the packet the full dose of SINGUlAIR oral granules must be administered immediately (within 15 minutes). If mixed with food, or dissolved in baby formula or breast milk, SINGULAIR oral granules must not be stored for future use. SINGULAIR oral granules are not intended to be dissolved in any liquid other than baby formula or breast milk for administration. However, liquids may be taken subsequent to
administration.
General Recommendations
The therapeutic effect of SINGULAIR on parameters of asthma control occurs within one day. SINGULAIR tablets, chewable tablets, and oral granules can be taken with or without food. Patients should be advised to continue taking SINGULAIR while their asthma is sontrolled  as,well as during period of worsening asthma
No dosage adjustment is necessary for pediatric patients, for the elderly, for patients with renal insufficiency, or mild to-moderate hepatic impairment, or for patients of either gender. Therapy with SINGULAR in Relation to other Treatments for Asthma SINGULAIR can be added to a patient’s existing treatment regimen.
Reduction in Concomitant Therapy:
Bronchodilator Treatments: SINGULAIR can be added to the treatment regimen of patients who are not adequately controlled on bronchodilator alone. When a clinical response is evident (usually after the first dose), the patient’s bronchodilator therapy can be reduced as tolerated. Inhaled Corticosteroids: Treatment with SINGULAIR provides additional clinical benefit to patients treated witn inhaled corticosteroids. A reduction in the corticosteroid dose can be made as tolerated. The dose should be reduced graduaHy with medical supervision. In some patients, the dose of inhaled corticosteroids can be tapered off completely. SINGULAIR should not be abruptly substituted for inhaled corticosteroids.
CONTRAINDICATIONS :
Hypersensitivity to any component of this product
PRECAUTIONS :
The efficacy of oral SINGULAIR for the treatment of acute asthma attacks has not been established. Therefore, oral SINGULAIR should not be used to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication available.
While the dose of concomitant inhaled corticos eroiamay be reduced gradually under medical supervision, SINGULAIR should not be abruptly substituted for inhaled ororal corticosteroids. The reduction in systemic corticosteroid dose in patients receiving anti-asthma agents including leukotriene recaptor antagonists has been followed in rare cases by the occurrence of one or more of the following:
eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy sometimes diagnosed as Churg-Strauss syndrome, a systemic eosinophilic vasculitis. Although a causal relationship with leukotriene receptor antagonism has not been established, caution and appropriate clinical monitoring are recommended when systemic corticosteroid reduction is considered in patients receiving SINGULAIR.
PREGNANCY :
singulair has not been studied in pregnant women SINGULAIR should be used during pregnancy only if clearly needed. During worldwide marketing experience, congenital limb defects have been rarely reported in the offspring of women being treated with SINGULAIR during pregnancy. Most of these women were also taking other asthma medications during their pregnancy. A causal relationship between these events and SINGULAIR has not been
established